Andrew Lee | Vice President, Program Executive
Vir Biotechnology, Inc.

Andrew Lee, Vice President, Program Executive, Vir Biotechnology, Inc.

Andy Lee, M.D., has been Vice President and Program Executive for the hepatitis program at Vir since January 2020. Prior to joining Vir, Dr. Lee led development of new vaccines and monoclonal antibodies in the department of Vaccines Clinical Research at Merck, including a pediatric hexavalent combination vaccine (VaxelisTM) that is licensed in the US and EU. Dr. Lee received his B.S. in Molecular Biophysics and Biochemistry from Yale, his M.D. from Cornell University Medical College, completed his infectious diseases fellowship at Stanford, and performed postdoctoral research at Rockefeller University and Stanford.


Day 2 - November 29 @ 15:00

Addressing the Unmet Need for a Functional Cure for Chronic Hepatitis B

Day 2 - November 29 @ 16:30

Panel: Toward a Hepatitis B-Free Future: Perspectives on Achieving a Functional Cure

  • How do you define a functional / partial cure – how should we use these terms and what are their limitations?

  • Which technologies/ modalities are we using to achieve a functional cure? What are the limits of different approaches? Can they be combined for more therapeutic benefit? (Antivirals, Antibodies, Vaccines, siRNA

  • Components to an effective cure strategy:

    o Use of viral replication inhibitors

    o Reducing viral surface antigen load – do we still have room to further reduce load?

    o Activation of antiviral immune response

  • Challenges in balancing side-effects and therapeutic efficacy

    How do we manage / avoid resistance


last published: 02/Jan/24 12:15 GMT

back to speakers